Have Questions?

Global Headquarters

Tel: +44 (0)20 7377 0800
Fax: +44 (0)20 7349 5157

North America

Tel: 1-617-573-9450
Fax: 1-617-573-9542

Japan

Tel: +81 (0)80-1164-4754

Request a Demo

What our customers are saying

When I think of the future, I think of EvaluatePharma

Senior Director,
Global pharmaceutical company

Press Release


Worldwide Medtech Sales Forecast to Reach $529.8 Billion by 2022

Annual “EvaluateMedTech World Preview 2016, Outlook to 2022” report shows continued medtech sector growth of 5.2 percent per year until 2022

Download PDF

LONDON, BOSTON, TOKYO, SAN DIEGO (October 17, 2016) — The total value of the global medtech market is expected to reach $529.8 billion by 2022, growing at an annual rate of 5.2 percent over the next seven years according to the “EvaluateMedTech World Preview 2016, Outlook to 2022” report from life science commercial intelligence firm Evaluate Ltd.

“Overall, the device industry is growing reasonably rapidly, and the calming of the M&A scene does not pose a problem for the expected growth,” said Ian Strickland, product manager for EvaluateMedTech. “The sector is already seeing a resurgence of smaller acquisitions on which start-ups, a significant source of disruptive new technologies, depend.”

“Most of this projected growth is driven by a number of new products that will come onto the market in the next seven years. However, there are several issues that could spoil this rosy picture of uninterrupted growth, including political scrutiny over pricing. The recent outcry over Mylan’s price increases for EpiPen – followed by the company’s repeated capitulations – show just how sensitive pricing models can be to political pressure,” said Antonio Iervolino, Head of Forecasting, Evaluate.

“As a result of this we expect companies to continue investing in pricing models strongly tied to real world benefits and consistently incorporate pricing and market access discussions at a much earlier stage in the clinical development process. So, while currently the industry does have plenty to celebrate, there are potential brakes on progress that could make the outlook much more mixed.”

EvaluateMedTech® World Preview 2016, Outlook to 2022 - Analysis Highlights:

  • Worldwide medtech sales forecast to reach $529.8bn by 2022
  • Medtronic remains top medtech company in 2022; sales forecast to reach $39.9bn
  • M&A activity in H1 2016 slumps 79% to $17bn following 2015’s flurry of mega mergers
  • Medtech R&D spend forecast to grow by 4.3% per annum to $34.0bn in 2022
  • Number of first-time PMAs and HDEs hits a ten-year high in 2015; 510(k) clearances decrease 6% to 3,064

The “EvaluateMedTech® World Preview 2016, Outlook to 2022” report is based on in-depth forecast models for the top 300 global medtech companies available within EvaluateMedTech®. This sales forecast represents the only current consensus view from equity analysts of the entire medtech market. The report can be downloaded at www.evaluategroup.com/MedtechWorldPreview2016. Ian Strickland, product manager for EvaluateMedTech®, will be available for discussion and comment at AdvaMed 2016. A hard copy of the executive summary will be available at Evaluate’s AdvaMed 2016 booth #407, which is taking place October 17-19, 2016 in Minneapolis, Minnesota.

About Evaluate Ltd.
Evaluate is the trusted provider of commercial intelligence including product sales and consensus forecasts to 2022 for commercial teams and their advisors within the global life science industry. We help our clients make high value decisions through superior quality, timely, must-have data and insights, combined with personalised, expert client support. Our online subscription services cover the pharmaceutical, biotech and medtech sectors. Our Custom Services group delivers project based analytical and data services. EP Vantage, our independent, award-winning editorial team, offers data-driven, forward-looking news, commentary and analysis on a daily basis.

For more information visit: www.evaluategroup.com. On Twitter: @evaluatepharma, @evaluatemedtech, @evaluateJP, @epclinicaltrial, @epvantage.

Back to Press Releases